← Leaderboards
Larissa Jeanette Mooney
University Of California Los Angeles
$11,651,967
Attributed
$23,303,933
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.7M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,303,933 · 7
By mechanism
UG1$15,755,868 · 1
R01$3,347,647 · 1
R33$3,301,361 · 2
R21$899,057 · 3
Top collaborators
- Yih-Ing Hser17 shared
- Edythe D London5 shared
- Kate Basia Wolitzky-Taylor2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Thomas Frederick Newton$18,826,829
- Steven Shoptaw$45,062,464
- Joseph Abiodun Ladapo$5,943,292
- Edythe D London$25,283,467
- Yih-Ing Hser$23,860,625
Others in their field
Top investigators on “Public Health”
- David R. Weir · University Of Michigan At Ann Arbor$416,847,438
- Jeffrey P Krischer · University Of South Florida$337,395,475
- Wafaa M. El-Sadr · Columbia University Health Sciences$336,205,398
- Elisabeth H Lyman · California St Dept Of Hlth Srvs-Sacramen$325,795,604
- Myron S Cohen · Family Health International$295,773,363
- George R Seage · Abt Associates, Inc.$292,142,010
Research focus
Public HealthPharmaceutical PreparationsResponsePharmacotherapyLeadUnited StatesInnovationDesignComorbidityOpioid Use DisorderBaseImproved OutcomeTreatment OutcomeMortalitySubstance Use DisorderOverdose DeathIntervention StudiesPatient Self-ReportCaliforniaBehavior TherapyTrainingImprove AccessResearch PersonnelMedical
Grant awards (24)
Greater Southern California Node of the Clinical Trials Network$682,265
UG1 · FY2025 · DA · contact PI
Greater Southern California Node of the Clinical Trials Network$662,494
UG1 · FY2023 · DA
Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids$162,342
R21 · FY2023 · DA
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function$635,862
R01 · FY2022 · DA
Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids$197,799
R21 · FY2022 · DA
Greater Southern California Node of the Clinical Trials Network$1
UG1 · FY2022 · DA
Greater Southern California Node of the Clinical Trials Network$6,327,088
UG1 · FY2021 · DA
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function$661,715
R01 · FY2021 · DA
Assessing Functional Outcomes Associated with Reductions in Cannabis Use$580,651
R33 · FY2021 · DA
Greater Southern California Node of the Clinical Trials Network$117,145
UG1 · FY2021 · DA
Greater Southern California Node of the Clinical Trials Network$4,227,936
UG1 · FY2020 · DA
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function$667,204
R01 · FY2020 · DA
Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder$540,706
R33 · FY2020 · DA
Assessing Functional Outcomes Associated with Reductions in Cannabis Use$539,935
R33 · FY2020 · DA
Greater Southern California Node of the Clinical Trials Network$120,879
UG1 · FY2020 · DA
Greater Southern California Node of the Clinical Trials Network$3,618,060
UG1 · FY2019 · DA
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function$681,239
R01 · FY2019 · DA
Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder$553,610
R33 · FY2019 · DA
Assessing Functional Outcomes Associated with Reductions in Cannabis Use$551,653
R33 · FY2019 · DA
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function$701,627
R01 · FY2018 · DA
Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder$534,806
R33 · FY2018 · DA
Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder$223,217
R21 · FY2017 · DA
Assessing Functional Outcomes Associated with Reductions in Cannabis Use$160,758
R21 · FY2017 · DA
Assessing Functional Outcomes Associated with Reductions in Cannabis Use$154,941
R21 · FY2016 · DA